Eli Lilly Zepbound — Revenue decreased by 2.4% to $4.16B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 79.9%, from $2.31B to $4.16B. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates strong market penetration, successful commercial execution, and growing patient demand for the therapy. A decrease may signal increased competition, supply chain constraints, or loss of market share.
This metric represents the total gross sales generated from the specific pharmaceutical product line indicated, net of r...
Comparable to revenue metrics for specific blockbuster drugs or key growth franchises reported by other large-cap pharmaceutical companies.
lly_segment_zepbound_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $176.00M | $517.40M | $1.24B | $1.26B | $1.91B | $2.31B | $3.38B | $3.59B | $4.26B | $4.16B |
| QoQ Change | — | — | — | — | — | — | — | — | — | — | — | +194.0% | +140.3% | +1.2% | +51.7% | +21.2% | +46.3% | +6.1% | +18.7% | -2.4% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +983.9% | +346.8% | +172.0% | +185.3% | +123.4% | +79.9% |